Delving into the Latest Updates on Chloroquine Phosphate/Azithromycin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Azithromycin/chloroquine, Chloroquine/Zithromax, Chloroquine/azithromycin

+ [1]

Target

50S subunit

Mechanism

50S subunit inhibitors(50S ribosomal subunit inhibitors)

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication-

Inactive Indication

MalariaMalaria, FalciparumParasitemia

Originator Organization

Pfizer Inc.

Active Organization-

Inactive Organization

Pfizer Inc.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC38H72N2O12

InChIKeyMQTOSJVFKKJCRP-BICOPXKESA-N

CAS Registry83905-01-5

An Open Label, Non-comparative Study To Evaluate Parasitological Clearance Rates And Pharmacokinetics Of Azithromycin And Chloroquine Following Administration Of A Fixed Dose Combination Of Azithromycin And Chloroquine (Azcq) In Asymptomatic Pregnant Women With Plasmodium Falciparum Parasitemia In Sub-saharan Africa

The study will be conducted in asymptomatic pregnant women with P. falciparum parasitemia. The subjects will be given 3 day dosing regiment of the fixed-dose combination of Azithromycin and Chloroquine. Parasitological clearance rate with polymerase chain reaction data will be evaluated on Day 28 as primary endpoint.

Start Date01 Mar 2011

Sponsor / Collaborator

Pfizer Inc.

NCT01103063 / TerminatedPhase 3

A Phase 3, Open Label, Randomized, Comparative Study To Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa

The primary objective is to establish superiority of AZCQ over SP in protective efficacy for IPTp as measured by the proportion of subjects with sub-optimal pregnancy outcome.

Start Date01 Oct 2010

Sponsor / Collaborator

Pfizer Inc.

[+2]

NCT01100060 / CompletedPhase 1

A Phase 1, Open-Label, Randomized, Single Dose, Parallel Design Study To Estimate The Relative Bioavailability Of Co Administered Formulations Of Azithromycin Microsphere (AZ) And Chloroquine Test Formulation (CQ) Compared With Co Administered Immediate Release Individual AZ And CQ Tablets In Healthy Adult Subjects

Estimate the relative bioavailability of co-administered azithromycin microsphere (2000 mg) and the chloroquine (620 mg CQ base) test formulation compared to co-administered immediate release individual tablets of azithromycin (2000 mg) and chloroquine (600 mg CQ base) in healthy adult subjects.

Start Date01 Apr 2010

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Chloroquine Phosphate/Azithromycin

Login to view more data

100 Translational Medicine associated with Chloroquine Phosphate/Azithromycin

Login to view more data

100 Patents (Medical) associated with Chloroquine Phosphate/Azithromycin

Login to view more data

100 Deals associated with Chloroquine Phosphate/Azithromycin

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parasitemia	Phase 3	KE	Pfizer Inc.	01 Mar 2011
Parasitemia	Phase 3	BJ	Pfizer Inc.	01 Mar 2011
Parasitemia	Phase 3	MW	Pfizer Inc.	01 Mar 2011
Parasitemia	Phase 3	UG	Pfizer Inc.	01 Mar 2011
Parasitemia	Phase 3	TZ	Pfizer Inc.	01 Mar 2011
Malaria	Phase 3	US	Pfizer Inc.	01 Feb 2009
Malaria, Falciparum	Phase 3	-	Pfizer Inc.	01 Jul 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01103063 (Pubmed \| J Biol Chem)	Phase 3	Malaria, Falciparum	2,891	Azithromycin-chloroquine	fewhzecehx(ojmytrwygk) = nazazultgt bgoeykonse (ytvmerrsbd ) View more	Negative	01 Jan 2016
				Sulfadoxine-pyrimethamine	fewhzecehx(ojmytrwygk) = cnaqxozbpc bgoeykonse (ytvmerrsbd ) View more